CAROL AGHAJANIAN

Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology NEW YORK, NY NPI 1275570533

General Payments — all program years on this page

$46,929.33

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 55
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $12,467.50 across 20 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Consulting Fee $12,467.5020

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
AstraZeneca UK Limited $12,467.5020

By program year

Program yearAmountRecords
2018 $5,706.8911
2019 $17,985.8111
2020 $7,123.753
2021 $155.954
2022 $149.431
2023 $3,340.005
2024 $12,467.5020

Records — PY2024 (20)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1093891480 AstraZeneca UK Limited $225.00 03/14/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1093902868 AstraZeneca UK Limited $112.50 09/15/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1093912777 AstraZeneca UK Limited $900.00 08/14/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1093913894 AstraZeneca UK Limited $500.00 11/06/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1093924569 AstraZeneca UK Limited $225.00 05/14/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1093938877 AstraZeneca UK Limited $112.50 06/13/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1093946066 AstraZeneca UK Limited $112.50 10/15/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1093948815 AstraZeneca UK Limited $225.00 07/12/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1093951839 AstraZeneca UK Limited $600.00 01/11/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1093952087 AstraZeneca UK Limited $225.00 05/14/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1093958471 AstraZeneca UK Limited $787.50 04/12/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1093971361 AstraZeneca UK Limited $2,740.00 06/28/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1093996501 AstraZeneca UK Limited $2,740.00 06/07/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1093996824 AstraZeneca UK Limited $900.00 09/15/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1094002209 AstraZeneca UK Limited $225.00 02/14/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1094002607 AstraZeneca UK Limited $112.50 06/13/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1094003988 AstraZeneca UK Limited $112.50 10/15/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1094007682 AstraZeneca UK Limited $112.50 07/12/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1094009470 AstraZeneca UK Limited $600.00 01/11/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1094030134 AstraZeneca UK Limited $900.00 12/15/2024 Consulting Fee Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.